Database analysis of ethnicity, sex, and insurance status of patients with Parkinson's disease by Cavanaugh, William Thomas
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Database analysis of ethnicity, sex,
and insurance status of patients
with Parkinson's disease
https://hdl.handle.net/2144/15716
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
DATABASE ANALYSIS OF ETHNICITY, SEX, AND INSURANCE STATUS OF 
PATIENTS WITH PARKINSON’S DISEASE 
 
 
 
 
by 
 
 
 
 
WILLIAM T. CAVANAUGH 
 
B.A., College of the Holy Cross, 2008 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 WILLIAM T. CAVANAUGH 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 Anna DePold Hohler, M.D., FAAN 
 Associate Professor of Neurology 
 
 
Second Reader   
 Marie Saint-Hilaire, M.D. 
 Associate Professor of Neurology 
 
 
Third Reader   
 Janice Weinberg, ScD. 
 Professor of Biostatistics 
 Harvard University, School of Medicine 
 
 
  iv 
ACKNOWLEDGMENTS 
 
I want to thank my thesis readers Dr. Saint-Hilaire and Dr. Weinberg, for their wisdom, 
their patience, and their direction during this process.  Their advice and comments have 
allowed me to make this thesis the best it can be.  I especially want to thank my thesis 
mentor Dr. Hohler for taking me on for this project, and for her guidance from the very 
first day to the submission of this thesis. 
 
  
  v 
DATABASE ANALYSIS OF ETHNICITY, SEX, AND INSURANCE STATUS OF 
PATIENTS WITH PARKINSON’S DISEASE 
WILLIAM T. CAVANAUGH 
ABSTRACT 
 Parkinson’s Disease (PD) is the second most common neurodegenerative 
condition in humans, after Alzheimer’s disease.  It can be observed in all races and both 
genders, in the United States and worldwide.  However, disparities in disease progression 
and manifestation exist between races and sexes.  In addition, treatment options and 
overall health, impacted by insurance type, may affect a PD patient’s disease state.  The 
purpose of this study is to contribute to the background demographic information of PD 
patients, particularly as pertaining to insurance classification, which has not yet been 
addressed in the literature. 
 
The Hoehn and Yahr (H&Y) scores of patients both ON and OFF medication, a method 
of ranking and analyzing disease severity in Parkinson’s patients, were analyzed in this 
study.  The hypothesis is that the H&Y scores are impacted by race, gender, and 
insurance status.  A univariate analysis of each variable was performed, the Student’s t-
test was used for gender and insurance status and a One-way ANOVA for race.  A 
multivariate regression model analysis was then run for the primary outcomes and 
included all the variables and known confounders.  A secondary analysis of disease 
complications utilizing Chi-square tests and logistic regression was also performed. 
  vi 
Gender and insurance status did not differ significantly in H&Y scores.  Black or African 
patients had a significantly increased PD progression as compared to Caucasian patients.  
Males and females differed significantly with regard to several disease complications.  
Subjects with public insurance also exhibited greater odds of some disease complications 
as compared to subjects with private insurance. 
 
In agreement with the literature, black PD patients exhibited a greater disease progression 
as compared to white PD patients.  However, the reason for this has not yet been 
adequately addressed.  In addition, more studies are needed to analyze other racial groups 
that were too small to appropriately address in this study.  Despite a lack of difference in 
H&Y scores, PD is observed to be manifested differently between genders (disease 
complications), also in agreement with the literature.  More studies are required to 
discover the reason for this disparity.  Insurance classification does not impact H&Y 
scores.  However, more studies are required to address whether this is maintained with a 
more sensitive outcome measure, such as the UPDRS.  In addition, some complications 
differ between insurance categories, implying a disparity in treatment options and 
therapies. 
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INTRODUCTION 
 Parkinson’s Disease (PD) was first described by James Parkinson in his 1817 
paper titled An Essay on the Shaking Palsy.
1
  However, this article did not garner much 
attention at the time, and was overlooked until the 1860s, when Jean-Marie Charcot used 
it to distinguish a condition he termed Parkinson’s Disease.  Charcot thoroughly explored 
this condition during his career, and he recorded many of the symptoms that are still used 
to characterize PD today.
2 
 
PD is the second most common neurodegenerative condition in humans, after 
Alzheimer’s disease.  The mean age of onset of the disease is in the early 60s, but up to 
10% of those with the condition have an onset prior to age 40.
3 
 
Total annual health-care costs are almost $12,000 greater for PD patients in the United 
States as compared to non-PD controls, and these values only increase as the disease 
progresses.
4
  The annual cost of PD in the United States is nearly $23 billion.  With a 
projected population of 80 million Americans who will be over 65 years of age in 2040, a 
conservative estimate of PD cost at that time will be $50 billion annually.
3 
 
Signs and Symptoms 
The external appearance of the brain in PD is often unremarkable, with no significant 
atrophy in the brainstem, white matter, or cortical brain areas.  Sections of the brainstem 
usually reveal a loss of dark pigmentation in an area named the substantia nigra (SN), 
 2 
which translates to “black substance”.  This loss of coloration in the SN correlates with 
neuronal loss.
5
  Neurons found in the SN area contain dopamine, a neurotransmitter 
important in relaying messages within the motor centers of the brain.
6
  Accompanying 
this deficiency of neurons is the added accumulation of protein aggregates named Lewy 
Bodies (LBs).  LBs are composed of filamentous material that includes the protein α-
synuclein exhibiting an abnormal conformation, and they are considered a hallmark of 
PD.  In addition to the LBs, tiny projections, also made up of α-synuclein, are observed 
growing from neurons and are referred to as Lewy neurites.
1 
 
The progression of PD has been characterized by the Braak staging system, which has 
been derived from autopsy studies of normal brains and those associated with LB-related 
diseases.
5 
  Stage 1 of the Braak stages is observed when Lewy neurites are found in the 
dorsal motor nucleus and the olfactory bulb, and this pathology worsens in stage 2.  Both 
of these stages are considered “pre-symptomatic”; although symptoms may be present, 
they are usually overlooked.  In particular, the damage to the olfactory bulb results in a 
loss in the sense of smell, an early warning sign of PD pathology.
7
  Also, during stage 2, 
the progression of the disease into the lower brainstem could result in many potential 
sleep or gastrointestinal symptoms.
1
   Therefore, if PD could be diagnosed at these early 
stages, the loss of neurons from the SN could be prevented, with adequate treatment.  
Stage 3 is when the disease progresses to the SN and the forebrain, and the first Lewy 
neurites are visible in these areas.  Stage 4 is a continuation of this progression, with the 
extent reaching further into the cortex to Ammon’s horn and the temporal mesocortex.  It 
 3 
is somewhere during the course of these two stages that the patient moves from the “pre-
symptomatic” phase into the “clinically-apparent” stage of PD, and motor symptoms 
manifest.  In the final stages, 5 and 6, the neurodegenerative process culminates – the SN 
appears pale and LBs are found in the cerebral cortex.  At this point, patients manifest the 
full range of PD-associated symptoms.
7
  The Braak classification, while useful, is 
somewhat controversial, as it relies on Lewy neurite formation alone, and not on neuronal 
degeneration.  In addition, the pathological progression as outlined by Braak is not seen 
in all PD brains.
1 
 
Due to the controversy of Braak’s stages and their reliance on autopsy verification, other 
forms of assessing disease progression have been developed that instead focus on 
symptoms.  A commonly used system is the modified Hoehn and Yahr, a classification 
that has been enhanced since its first emergence in the 1967 paper.
8
  This system begins 
at stage zero, in which there are no signs of the disease up to stage five, when the patient 
is wheelchair-bound or bedridden.  However, PD is a very complex disease with 
indicators that manifest in several areas other than motor symptoms.  The Unified 
Parkinson’s Disease Rating Scale (UPDRS) is a composite scale that includes several 
aspects of PD such as mood, cognitive symptoms, activities of daily living, disease 
severity, and a disability scale.
9
  The UPDRS has also been modified and includes the 
modified Hoehn and Yahr scale as part of its analysis.
10 
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Early symptoms of PD may be nonspecific – fatigue, muscle cramps, joint stiffness, sleep 
disturbances, constipation, and bladder dysfunction.
11
  In addition, other signs may 
emerge, such as a stooped posture, limping or dragging of one leg, a loss of the sense of 
smell, and a softness of voice.
6
  The loss of dopamine from the substantia nigra results in 
classical symptoms of PD, characterized by the acronym TRAP.  T is for “tremor. R is 
for “rigidity” (muscle stiffness).  A is for “akinesia” (loss 0f voluntary movement and 
fluid motion).  P is for “postural instability” (difficulties with balance and gait).6 
 
The age of onset of PD is usually between 50 and 60 years, but can actually range from 
childhood to eighty or ninety years of age.  The progression of the disease is just as 
variable as the age of onset.  Overall, the average amount of time in each Hoehn and 
Yahr stage (0-5) is estimated to be two-three years, and the average decline in the 
UPDRS is approximately two and a half points per year.  Without medication, PD has a 
thirteen year duration and an average age of death of 73 years.  Due to recent advances in 
PD medication and treatment, PD mortality has been reduced and patients live longer, 
although they still exhibit a higher mortality rate than age-matched controls without PD.
12
  
Patients with PD usually succumb to secondary problems associated with the disease, the 
two most common of these being falls and pneumonia.
6 
 
Risk Factors 
Aging is the single most significant factor in the clinical presentation, course, and 
progression of PD.
13
  In any population studied, an increase in PD frequency is associated 
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with increasing age.
14
  This can be observed across all races and both sexes,
15
 in the 
United States,
16 17
 in other countries,
18
 and overall worldwide.
19
  Current US prevalence 
values for PD are 553/100,000 for people in the age group 65-69, but rise to 
2949/100,000 for people over the age of 85.
15
  In some studies, a decrease in PD 
prevalence is observed later in life – but whether this is a true decrease or whether it is 
merely a difficulty in identifying PD in the very old is still unknown at this time.  Should 
such a decrease be real, however, it would suggest a biological “window of vulnerability” 
in developing the disease.
14 
 
Head trauma has been controversial in its relationship to PD.  A case study was published 
in 1999 regarding a patient who seemed to develop PD six weeks after an acute head 
trauma.  A case was then made to explain why the trauma itself was the most likely cause 
of PD.
20
  Scientists agree that head trauma can lead to PD-like symptoms,
1
 and most 
adhere to the notion that head injuries are associated with PD,
21
 but many believe that 
head trauma does not directly cause PD.  The head trauma would have to be severe 
enough to disturb the dopamine system and its connections.  In addition, the PD-like 
symptoms seen in head trauma patients diminish in time, and do not respond to well to 
anti-parkinson medication.
6
  Despite these facts, there is a documented relation between 
head trauma and PD, and a dose-dependent increased risk associated with more frequent 
or more severe head injuries.
14
  It has been stated that this type of association could be 
due to recall bias, in which patients with PD more easily remember and report head 
trauma than controls, who may forget past injuries and underreport true values.  In 
 6 
addition, the case has been made that head trauma and PD have a reverse causality – in 
other words, the motor disturbances associated with PD lead to more head injuries.
22
  
However, laboratory studies have suggested that chronic head injuries could affect 
oxygen delivery to the brain and encourage dysfunction in vulnerable systems, such as 
the dopamine delivery system.
14
  In addition, head injury has been associated with α-
synuclein accumulation in both animal models and post-mortem studies, and may initiate 
or accelerate the progression of the disease in individuals with already high α-synuclein 
levels due to mutations.
23 
 
Race 
Racial differences between PD patients have been addressed and documented.  While PD 
is found in all racial and ethnic backgrounds, Caucasians have a substantially higher 
incidence (new diagnoses of PD) and prevalence (number of patients diagnosed with the 
disease at any given time) of PD than blacks or Asians in the United States, with the 
highest incidence and prevalence found in the Midwest and the Northeast.  Previous 
studies performed on incidence and prevalence report smaller numbers than the 
nationwide study performed by Wright Willis, et al, but despite the growth in incidence 
and prevalence, non-Hispanic whites always have higher values than blacks.
15
  Despite 
these consistent comparisons between incidence and prevalence in white and black 
communities, black patients are diagnosed with PD at half the rate of white patients, even 
when several other potential confounding factors are controlled – factors such as age, sex, 
healthcare use, and geographic location.
24
  What is interesting, but as yet unexplained, are 
 7 
the high incidence and prevalence values in the Latino community.
16
 
25
 Despite the lower 
incidence and prevalence in their community, black PD patients exhibit greater disease 
severity and disability than white patients.  This could be due to limited access to care, 
economic factors,
26
 or the under-reporting of symptoms that result in a later diagnosis.  
This under-reporting could be the result of limited social support from the family and 
community, or a lack of trust in physicians that treat minority patients.
27 
 
Gender 
Sex also plays a role in PD.  It has been reported that males are 1.5 times more likely to 
develop PD than females,
1
 although some studies have found higher prevalence rates in 
females.
28
  It has also been claimed that the pattern of risks and protective factors differ 
between men and women in regards to developing PD.
29
  Various studies reported 
women have either greater,
30
 less,
31
 or the same disease severity as men,
32
 but it is 
consistently observed that women report worse overall quality of life.
30 33
 Women are 
more likely to evaluate symptoms as they relate to how they organize, build social 
relationships, and think, while men evaluate symptoms as they affect their appearance 
and strength.
34
  Men exhibit an increase in weight, daytime sleepiness, dribbling saliva, 
interest in sex, and problems having sex,
35
 while fatigue, feelings of nervousness and 
sadness, constipation, restless legs, and pain were more common and severe in women.
36
  
Depressive symptoms are more frequently observed in females PD patients  and tend to 
be more severe – as the disease progresses, so does the frequency of depression.37  The 
first symptom seen in women is most likely tremor.
32
  In addition, dyskinesias are more 
 8 
prevalent in women
38
 and thought to be potentially caused by higher doses of L-dopa.  
Since women, on average, weigh less than men, they subsequently receive a higher dose 
per kilogram of Levodopa, as PD patients are usually treated with standard dosages 
without adjustment according to body weight.
39
  The age of onset of PD is later in 
women, and positive correlations have been identified between the age of onset and the 
age at parity, menopause, and the length of the fertile life span.
40
  Therefore, a link 
between PD and estrogen has been hypothesized.  Recent studies have shown estrogen to 
be protective
41
 and estrogen replacement therapies as possible treatments for PD.
30
  
Overall, the lifetime risk of developing PD is 4.4% for males and 3.7% for females.
3 
 
Environmental Conditions 
Approximately 10% cases of PD are thought to stem solely from inherited genetic 
factors.  The remaining cases are considered to be caused by some unknown 
environmental factors to some degree.
42 
 
In the 1980s, an interest was fostered in the relationship between pesticides and PD.  This 
was brought about by the discovery that 1-methyl-4-phenyl, 1, 2, 3, 6-tetrahydropyridine 
(MPTP), a substance structurally similar to the herbicide paraquat, resulted in chronic PD 
symptoms and degeneration of dopamine-secreting neurons in humans.  Since then, 
paraquat and many other pesticides such as rotenone, maneb, dieldrin, heptachlor, and 
atrazine have been extensively studied to determine if a causal link to PD could be 
discovered.
43
  It has been stated that exposures to pesticides, herbicides, and insecticides 
 9 
all increase the risk of developing PD,
44
 and that this risk is dependent on the amount of 
exposure.
45
  However, there is still debate whether pesticides, herbicides, insecticides, 
and fungicides increase the risk or somehow cause PD, and studies performed on specific 
compounds provide variable results.
43 
 
Paraquat is a broad-spectrum herbicide used widely in developing countries, and is one of 
the most commonly used herbicides worldwide, although it is restricted in the United 
States.  Paraquat injections into mice elicit a dose-dependent decrease in movement and 
the number dopamine cells in the substantia nigra.
42
  However, the link between 
experiments in rodents and potential human adverse effects is weak.  Despite increased 
risks reported in many papers throughout the years,
43
 some claim that the clinical 
evidence is inconsistent and inconclusive.  Thus, more studies must be performed to 
answer the question of paraquat toxicity in humans, and its potential role in causing PD.
46
 
 
Rotenone is a naturally occurring compound that is found in the roots and leaves of 
several plant species.  It has been used extensively as an insecticide and also as a 
piscicide.
42
  Rotenone acts through mitochondrial inhibition and is thought to interfere 
with normal mitochondrial pathways, thus causing dysfunction and cell death.
47
  Much 
like paraquat, studies performed on rotenone result in variable outcomes, and it is 
unknown whether rotenone is a causative risk factor for PD.
43 
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The risk of PD appears to be increased in rural dwellers, especially in the United States.  
This may be due in part to pesticide use (as described above), combined with well-water 
drinking, both of which occur very frequently in rural communities.
14
  Drinking well 
water has been correlated to an increased risk of developing PD,
48
 since it is thought that 
pesticides seep into well water through the soil, thus introducing higher amounts of 
chemicals with PD-associated risk to rural communities.  Some studies have reported that 
PD patients were more likely to drink from private wells and to have drunk well water 
longer than controls.  While rural living appears to possess a higher risk of PD attached, 
there is very little evidence to support a relationship between specifically rural living (and 
not the risk factors associated with it, such as pesticides) and PD.
43
  Therefore the 
association is thought to be due to the combined action of pesticides and drinking well 
water.
49 
 
Rural communities are not the only population found to be at an elevated risk of 
developing PD.  Solvents are a broad range of chemicals that act as a means to dissolve 
one substance into another.  The most common solvents in use today are 
trichloroethylene (TCE), toluene, acetone, hexane, carbon disulfide – all of which serve 
multiple purposes.  Exposure to these chemicals is usually through inhalation or through 
the skin.
50
  Occupational exposures are common in dry cleaning, metal de-greasing, and 
paint stripping occupations.  Although long considered as possible PD risk factors, 
solvents have received less attention than pesticides or metals, despite widespread use in 
many workplaces.
51 
 11 
 
TCE is a highly volatile organic chemical that has been used for many years, and is a 
major environmental contaminant in industrialized countries.  Reports have linked PD 
with long-term exposure to TCE in humans, although this does not denote a causal 
relationship.
42
  Three studies have shown that rodents given high doses of TCE orally 
exhibit a depletion of dopamine-supplying neurons in the substantia nigra.  However, 
this does not translate well to humans, as the primary mode of exposure in humans is 
through inhalation, and usually at low doses.  In addition, it is not known whether TCE or 
one of its metabolites is damaging the neurons in rodents, and if a similar model occurs in 
humans.  At present, there is no clear toxicological or epidemiological evidence of any 
specific solvent or class of solvents as a cause of PD, but further research is necessary in 
this field.
51 
 
Metals are utilized in a plethora of biological processes in nearly every organism on 
Earth, due to properties that increase the rates of enzyme reactions, among other qualities.  
While toxic effects of metal exposure on the human body have been well documented, it 
has only been recently that the effects of metal toxicity in the brain have been addressed.  
Metals have long been thought to play a role in PD.  Of particular interest are iron, 
manganese, lead, copper, and mercury.
50
  Iron accumulates in the substantia nigra of PD 
patients, but this does not have a correlation with dietary iron intake, and therefore the 
accumulation is most likely due to environmental factors or disorders or iron uptake or 
transport.
42
  Both copper and lead exposures have been associated with increased risk of 
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PD, although copper is necessary for normal human biologic functions, while lead is a 
non-essential metal that most often interferes with normal biologic functions.
50
  In 
addition, combined exposures of lead-copper, lead-iron, and iron-copper all result in 
significant association with PD.
14
  While it has been established that mercury exposure 
causes significant motor symptoms, and has been known to result in neurological 
alterations since the 1800s, there has been no established association between mercury 
and PD, although a major amount of data suggests that mercury exposure can impact the 
dopamine system in the brain.
50
  Manganese is the 12
th
 most abundant element in the 
earth’s crust and is essential for human biology.42  Elevated manganese exposure can 
occur in miners and welders, although a recent meta-analysis found a decreased risk of 
developing PD in the welding occupation, and no association between manganese 
exposure and PD.
52
  While manganese exposure leads to PD-like symptoms (called 
manganism), and accumulated manganese in the mitochondria can cause dysfunction (a 
feature thought to contribute to PD), there is weak evidence linking manganese exposure 
to PD, and many believe manganism to be a separate entity with similar output symptoms 
to PD.
50 
 
There is also an additional risk factor to a very specific group of people.  During the 
Vietnam War, several toxic herbicides (called Agent Orange) were used for military 
purposes starting in 1961, and many war veterans were exposed to Agent Orange during 
that time.
53
  It has been reported that people (both veterans and civilians) exposed to 
Agent Orange exhibited an increased risk of developing PD.
54 
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Identifying a single causative environmental agent that is responsible for a significant 
number of cases has been difficult, and as yet, still incomplete.  The general conclusion is 
simply that it is more likely that multiple exposures over time from numerous high risk 
agents in conjunction with a background of genetic risk factors are responsible for most 
cases of PD.
42
  There may be an additional effect from various exposures – one paper 
found that exposure to paraquat and head trauma increased the risk of developing PD 
more than either risk factor alone.
21 
 
Genetics 
Up until the 1990s, PD was believed to be an environmentally caused disorder with little 
or no genetics component, and this is probably due to the fact that more than 70% of PD 
patients report no prior family history of PD.
55
  However, it has been reported that a first-
degree relative of a PD patient is approximately twice as likely to develop PD compared 
to controls,
49
 although this relative risk may vary between early and late-onset PD,
56 57
 
between parent-to-patient relationships and sibling-to-patient relationships,
58
 and between 
races.
59 
 
The genes associated directly with PD are LRRK2, PARK2, PARK7, PINK1, and SNCA.  
Genes that do not appear to cause PD but instead modify the risk for developing the 
condition are GBA and UCH-L1.
60
  SNCA (also called PARK1/PARK4), LRRK2 (also 
called PARK8) and UCH-L1 (also called PARK5) are all considered autosomal dominant 
 14 
genes, while PARK2, DJ-1 (also called PARK7), and PINK1 (also called PARK6) are all 
considered autosomal recessive genes.
61 
 
The SNCA gene codes for the protein α-synuclein, a protein whose function is largely 
unknown, although it has been hypothesized that α-synuclein may be involved with 
dopamine storage and recycling.  Mutations in this gene result in α-synuclein proteins 
that can polymerize and aggregate into fibrils, and these aggregates are a major 
component of LBs.
55
  Mutations in the SNCA gene also correlate to an earlier mean age 
of disease onset compared to other PD patients and a higher rate of dementia.
49
 
PARK2 codes for the parkin protein, and it is one of the largest known human genes, 
spanning more than 500 kb.  Patients with a mutation in PARK2 have an earlier disease 
onset than other PD patients and a relatively slow disease progression.
55
  It is thought that 
parkin aids in normal cellular protein degradation pathways.  Without the parkin protein, 
other cellular proteins may not be degraded and removed from cells as efficiently as 
necessary, causing microtubule and mitochondrial dysfunction, and eventually cell 
death.
49 
 
The UCH-L1 gene codes for the ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) 
protein.  Much like the parkin protein, UCH-L1 is thought to aid in protein degradation 
and clearance from neurons.  Defects in the gene lead to protein accumulation and 
aggregation, including the UCH-L1 protein itself, which can also be found in LBs along 
with α-synuclein in PD patients.55  As yet, no specific mutation has been linked between 
 15 
the UCH-L1 gene and PD, despite extensive screening.  For this reason, the UCH-L1 
gene is indirectly related to the risk of developing PD.
49 
 
Much like mutations in PARK2 and the parkin protein, mutations in the autosomal 
recessive PINK1 gene result in an earlier onset of PD and a slow disease progression.  
However, having a single PINK1 mutation may predispose patients to have typical late-
onset PD.
55
  Phosphatase and tensin (PTEN)-induced putative kinase 1 (PINK1) is 
thought to regulate the electron transport chain in the mitochondria, a series of reaction 
used to generate cellular energy.  In addition, PINK1 maintains the mitochondrial 
membrane potential as it pertains to programmed cellular death.  Therefore, mutations in 
PINK1 lead to mitochondrial dysfunction and may lead to early cell death in neurons.
49
 
 
The clinical phenotype associated with autosomal recessive DJ-1 is not well 
characterized due to its rarity, but it appears to be similar to parkin and PINK1 related 
parkinsonism.  The gene codes for a protein ubiquitously found in mitochondria in brain 
tissue, and can aggregate with both parkin and α-synuclein when mutated.  It normally 
protects against oxidative stress, regulates RNA-binding proteins, and prevents protein 
aggregation.  Therefore, all of these processes are interrupted with DJ-1 gene mutations.
55 
 
Mutations have been found throughout LRRK2’s gene domains, and despite the relatively 
uniform disease progression seen with those mutations, the neuropathology can vary 
greatly, even between family members carrying the same mutation.
49
  LRRK2-related PD 
 16 
often presents as a late-onset form of the disease.  Leucine-Rich Repeat Kinase-2 
(LRRK2) is found throughout the brain in the cytoplasm of cells, and functions as a 
kinase which interacts with the outer membrane of mitochondria.  Mutations result in a 
dominant inheritance of the disease, perhaps through a toxic gain of function from 
increased phosphorylation on the mitochondrial membrane.  LRRK2 protein interacts 
with the parkin protein, but not DJ-1, Tau, or α-synuclein.55 
 
Gaucher’s disease is the result of an autosomal recessive inheritance of a mutated 
glucocerebrosidase (GBA) gene.  This disease state is characterized by lipid 
accumulation in bone marrow, lungs, spleen, liver, and sometimes the brain.
62
  One rare 
manifestation of Gaucher’s disease is early-onset parkinsonism.55  Therefore, the GBA 
gene is considered a PD susceptibility gene.  A study found 14% of PD carried mutations 
in this gene as compared to 5% of controls.
49 
 In fact, those people with a GBA mutation 
(with or without Gaucher’s disease) are five times more likely to develop PD than those 
without the mutation.
63
 
 
As stated before, PD was considered to be environmentally triggered until the last twenty 
years.  Much is now known about the genetic aspects to PD, and studies continue to be 
performed in order to elucidate the gaps in knowledge.  Recently, six new genetic risk 
factors of PD were identified by scientists in the National Institutes of Health (NIH).
64
  
Thanks to ongoing studies and the various animal models available,
65
 the genetics 
surrounding PD can be analyzed, tested, and clarified. 
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Treatment 
Since 1967, levodopa (L-dopa) has been a major medication for treating PD and remains 
the “gold standard” of treatment.66  L-dopa is currently the most effective treatment for 
PD and is required by almost all patients as the disease progresses (refer to Figure One 
for levodopa’s metabolism and the sites where certain therapies are active).67  An early 
finding in the pharmacologic properties of dopamine is that it does not penetrate the 
blood-brain barrier, a highly specific mechanism inside the cranial blood vessels that only 
permit certain substances to reach the brain.  In other words, dopamine cannot cross from 
the blood into the brain tissue where it is lacking in PD patients.  However, its amino acid 
precursor (levodopa) can cross the barrier and enter the brain, where it is converted to 
dopamine via the enzyme dopa decarboxylase.  This enzyme is found in other areas of 
the human body as well – the gastrointestinal tract, kidneys, liver, and other areas.  This 
means that levodopa can be turned into dopamine in the blood before it crosses the blood-
brain barrier, so less L-dopa reaches the brain.  It can also result in high levels of 
dopamine in the blood, causing nausea and vomiting, and in some rare cases, cardiac 
arrhythmias and hypotension.  To prevent this, L-dopa is combined with peripheral dopa 
decarboxylase inhibitors (DDIs), which would block the enzyme in all body locations 
except the brain.  Not only does this reduce the side effects of L-dopa treatment, it also 
allows for smaller, but more effective, dosing regimens of levodopa.  Due to the success 
of DDIs, L-dopa is only available in combination with a DDI.  In the United States, the 
only approved DDI is carbidopa, although benserazide is available in other countries.
6
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Levodopa is a large neutral amino acid and is absorbed in the proximal small intestine by 
active transport.  Therefore, the presence of other amino acids (from a patient’s diet) will 
compete with L-dopa for absorption into the blood, and reduce the overall levodopa 
blood level.  L-dopa also does nothing to protect the dying neurons, and therefore as PD 
continues to progress, there is a diminished capacity for neurons to store and convert L-
dopa into dopamine.
66
  This contributes to the appearance of motor complications that 
occur from prolonged use of L-dopa.  These complications occur in 40% of patients after 
5 years of therapy, and 100% of patients after 10 years.
67 
 
One type of motor complication is called “motor fluctuations”.  Motor fluctuations are 
the emergence of periods when PD symptoms increase despite L-dopa medication.  It is 
not known whether these periods are caused by levodopa or are a consequence of disease 
progression.
6
  The fluctuations are alternations between “on” time, when symptoms are 
controlled, and “off” time when the symptoms return.  End-of-dose wearing off is the 
most common motor fluctuation, and occurs when a single L-dopa dose begins to wear 
off, and symptoms begin to return.  This effect usually happens at predictable times.  As 
the disease progresses, a longer period may be observed before a dose of levodopa begins 
to take effect, or symptoms may begin to reoccur earlier and earlier, or an “off” period 
may occur quickly and unexpectedly.  Motor fluctuations are usually the most common 
reason for increasing the dose of L-dopa.
67 
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Dyskinesia (coming from the root words for “difficult” and “movement”) is a condition 
in which a person has involuntary, writhing movements, often described as choreiform.
6
  
These movements can involve the face, head, neck, arms, legs, torso, and respiratory 
muscles.  The most common type of dyskinesia is peak dose, which occurs when L-dopa 
blood levels reach their highest concentrations.  Less commonly, dyskinesia can occur 
when the effects of levodopa are beginning and/or when the effects are wearing off.
67
  
Dyskinesia can also take the form of painful muscle spasms known as dystonia.  Dystonia 
occurs most often when drug levels are very low.
6
  The ELLDOPA study in early PD 
patients suggests that higher doses of L-dopa lead to higher frequency of dyskinesia.
1
 In 
this study, 30% patients on the highest L-dopa exposure (600mg) demonstrated wearing-
off motor fluctuations and 16.5% developed dyskinesia in less than a year’s time.66  
Recent human MRI studies in PD patients with dyskinesia have suggested neuro-
anatomical changes in specific brain regions, particularly the frontal cortex.  It is unclear 
whether these abnormalities are the cause or the result of dyskinesia, but further studies 
may link neuro-imaging with neuropathology and lead to the discovery of novel anti-
dyskinetic treatments.
68 
 
 L-dopa therapy should be started at the minimal effective dose and increased as 
necessary.
1
  Carbidopa/levodopa is commercially available in tablet form as Sinemet, or 
as an orally disintegrating tablet as Parcopa, when swallowing becomes difficult (for 
these and all future drug information, please refer to Table One).
67
  Orally disintegrating 
tablets have been shown to increase patient adherence to drug regiments, due to the ease 
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of drug administration.
69
 This is important, as 8–11% of hospitalizations in elderly 
patients in the general population are attributable to non-adherence of their medication.  
Non-adherence is also associated with a twofold increase in costs of inpatient care.  In 
particular, the consequences of non-adherence in PD include worse disease control, 
diminished mobility, greater fluctuations, dyskinesias, and worsening quality of life.  
Much like the general population, PD patients who do are non-adherers have significantly 
higher rates of yearly hospitalizations and a $3,451 yearly increase in medical costs as 
compared to medication-adhering PD patients.
70 
 
Another commercially available carbidopa/levodopa medication is Sinemet CR, an 
extended-release form of Sinemet.  The extended-release provides a slower release of 
dopamine into the bloodstream, producing a longer duration of L-dopa’s effects.  L-dopa 
has a short half-life (about 90 minutes), thus requiring frequent medication daily.  The 
extended-release form allows for decreased dosing frequency.  However, this form of 
levodopa also takes longer to take effect after the first dose, thus forcing PD patients to 
endure their motor symptoms for more time initially (for example, when they wake up 
and all medication has worn off during the night) than the more immediate-release 
treatments.
6
  In addition, the extended-release tablets have reduced bioavailability than 
the immediate-release forms, and less overall L-dopa enters the system.
1
  Clinicians can 
use a combination of both immediate-release and extended-release L-dopa to achieve a 
sustained dopaminergic response.
69 
 In fact, a new PD drug was recently approved that 
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has both immediate-release and extended-release forms of carbidopa/levodopa combined 
in a single tablet (Rytary). 
 
Other forms of levodopa may be available in the future.  Gastro-retentive delivery 
systems, such as floating delivery systems or the so-called accordion pill (because it 
unfolds inside the stomach), will enable medication to remain in the stomach for 
extended periods of time, thus achieving sustained release of the medication and 
requiring less frequent dosing.  There is a U.S. patent for an inhaled form of L-dopa 
which is being tested.  Currently available in Europe and recently approved in the United 
States is a portable pump that delivers a gel formulation of levodopa/carbidopa directly to 
the duodenum, Duopa.
69
  In other words, there is much research being performed to best 
introduce L-dopa into the body and enhance its medicinal effects.  At the same time, 
medications and research to reduce the side effects of L-dopa (motor complications) are 
also being explored. 
 
COMT (Catechol-O-Methyltransferase) inhibitors can be used in conjunction with 
levodopa/carbidopa in PD patients to lengthen L-dopa’s duration of action.71  This is 
done by blocking the COMT enzyme, which breaks down levodopa into 3-O-
Methyldopa, homovanillic acid, or 3-methoxytyramine - waste products that are removed 
from the system.
67
  Thus, L-dopa’s half-life is extended and more is able to enter the 
brain from the blood.
71
  Of the several types of COMT inhibitors, only entacapone and 
tolcapone have been studied in clinical trials.
72
 The STRIDE-PD study, in which patients 
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were randomized to either levodopa /carbidopa or levodopa/carbidopa/entacapone, was 
performed to address the effects of entacapone.  In this study, those exposed to 
entacapone exhibited a 30% increase in plasma L-dopa levels.
1
  Both entacapone and 
tolcapone increase the “on” time of L-dopa medication and decrease the “off” time.72  For 
this reason, COMT inhibitors are particularly helpful for people with motor fluctuations, 
as they reduce the wearing-off effect.  On the other hand, COMT inhibitors may pose 
problems for patients with dyskinesia, especially if these symptoms occur at the peak of 
the levodopa dose.
6
  There are other potential problems with COMT inhibitors as well.  
Tolcapone appears to be more potent than entacapone, most likely due to the fact that 
tolcapone can cross the blood brain barrier and block COMT in brain tissue, while 
entacapone cannot.  However, tolcapone was observed to cause abnormal liver function 
that could result in death.  For this reason, it was withdrawn from the market in Europe 
and Canada, and a black box warning was instituted in the United States.
73
  Since then, 
the drug has been allowed to return in Europe, with more strict safety restrictions.
74
  It is 
recommended that in patients taking tolcapone, liver enzyme testing should be every 2-4 
weeks for the first six months, and then when clinically indicated after that.
67
  Due to the 
success seen with COMT inhibitors, a triple combination of 
carbidopa/levodopa/entacapone (Stalevo) was created for patient convenience.
71 
 
Monoamine oxidase (MAO) plays an integral role in the metabolism of intra-cerebral 
dopamine, and inhibitors of this enzyme provide a therapeutic effect in PD patients.
75
  
Much like COMT inhibitors prevent the breakdown of L-dopa, MAO inhibitors prevent 
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the breakdown of dopamine.
67
  The MAO enzymes are one of two subgroups – A or B.  
MAO-A inhibitors and nonspecific MAO inhibitors that inhibit both A and B types 
relieve depression by increasing the amount of dopamine and norepinephrine in the brain.  
Those patients taking these types of medications must adhere to dietary restrictions due to 
the “cheese effect”.  This “effect” is a phenomenon in which patients who ate foods rich 
in tyramine (such a red wines, chicken liver, and cheeses) experienced dangerous 
hypertensive episodes while taking nonspecific MAO or MAO-A inhibitors.  However, 
MAO-B inhibitors are more specific and PD patients do not need to apply these dietary 
restrictions.
6
 MAO-B inhibitors provide a modest symptomatic benefit in the treatment of 
early PD, weaker than the benefits seen with L-dopa or dopamine agonists.  It is thought 
that MAO-B inhibitors may be best used in early stage patients with milder symptoms 
before using L-dopa medication.
76
  In addition to the positive effects seen from MAO-B 
inhibitor therapy as they pertain to PD motor symptoms, there is also evidence that these 
treatments also improve cognition and executive functions in PD patients.
77 
 
There are two MAO-B inhibitors used in PD treatment, selegiline and rasagiline.  
Rasagiline is available in tablet form (Azilect).  Selegiline is available in a pill form 
(Eldepryl) or in an oral disintegrating tablet (Zelapar).
67
  There is currently a transdermal 
delivery of selegiline available to treat depression, but it is not yet indicated for PD 
treatment.  However, an in vitro study exhibited promising results.
69 
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Selegiline is a selective, irreversible MAO-B inhibitor, which forms a permanent 
covalent bond with the enzyme, and reversal of its effects requires the production of new 
enzymes.
75
  As a single therapy, selegiline shows a modest symptomatic benefit for PD 
patients, and can delay L-dopa therapy.  Combined with levodopa, selegiline can reduce 
motor fluctuations.
76 
 Side effects of selegiline usually include nausea, dizziness, 
hallucinations, and anxiety.
75 
 It was thought that treatment with selegiline leads to an 
increased mortality rate, but these concerns have been rejected based on large meta-
analyses.
74
  In animal models, selegiline blocks the ability of MPTP to cause 
parkinsonism.  For this reason, it was thought that selegiline might posses some neuro-
protective properties and therefore slow the progression of PD.
1
  Therefore the 
DATATOP study was designed to determine selegiline’s effects in early PD patients that 
have not yet begun L-dopa treatment.  Due to selegiline’s modest therapeutic effects, the 
group of patients taking selegiline exhibited better UPDRS scores than those in the 
placebo group.
75
  However, follow-up studies and long-term studies revealed that 
selegiline has no neuro-protective effect.
6 
 
Rasagiline is also a selective irreversible MAO-B inhibitor that is prescribed alone or 
together with levodopa for PD treatment.  It is considered that rasagiline is five times 
more potent than selegiline.
1  
The higher potency suggests a greater symptomatic benefit, 
although studies claim them to be equally effective at treating PD in early stages.
78
  
Rasagiline reduces motor fluctuations and results in less “off” time from medication.6  
Side effects include dry mouth, headache, nausea, and abdominal discomfort.
75 
 Much 
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like selegiline, rasagiline was thought to be neuro-protective, and two studies, TEMPO 
and ADAGIO, were conducted to address this hypothesis.  However, the results were not 
conclusive, and controversy still surrounds the neuroprotective benefit of rasagiline.
76
 
 
Dopamine and dopaminergic drugs interact with one or more of the five known subtypes 
of receptors: D1, D2, D3, D4, and D5.  These receptors are usually grouped into 
stimulatory (D1 & D5) or inhibitory (D2, D3, & D4) families.  The efficacy of L-dopa is 
primarily due to the stimulation of the D2 receptors.
79 
 However, levodopa does not halt 
the progression of the disease, nor does it regenerate the neurons that have been lost.  The 
dopaminergic neurons that degenerate during the course of PD are necessary to transform 
levodopa into its functional form, dopamine.  As PD becomes more advanced, this 
process of converting L-dopa into dopamine becomes impaired.  It is for this reason that 
dopamine receptor agonists are used.  An agonist is a drug capable of combining with 
receptors and imitating the action of a neurotransmitter.  A dopamine receptor agonist, 
therefore, mimics the activity of dopamine and relieves the symptoms of PD.
6 
 There are 
also several other advantageous aspects to dopamine receptor agonists.  They work 
directly on the dopaminergic receptors without needing to be modified, released, or 
stored by the body.  They have longer half-lives than L-dopa and produce more persistent 
stimulation than levodopa alone.  Usually, dopamine receptor agonists are prescribed 
early in PD progression to postpone the onset of levodopa therapy.
80 
 This is particularly 
useful, as dopamine agonists can reduce or delay the motor complications associated with 
L-dopa therapy (motor fluctuations, and, to a certain extent, dyskinesias).
79 
 Despite this 
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advantage, it has been shown that levodopa provides more symptomatic benefit (based on 
UPDRS scores), and patients taking dopamine receptor agonists are also more likely to 
display dizziness, constipation, hallucinations, edema, and nausea.  Depending on the 
dosage, dyskinesias can either be more pronounced or less pronounced with dopamine 
receptor agonist therapy.
81 
 
Pramipexole (Mirapex) is a dopamine receptor agonist with a high affinity for D2, D3, 
and D4 receptors.  It has been shown in several clinical trials to decrease daily “off” 
time.
67 
 In addition to alleviating motor symptoms, some clinical trials have suggested 
pramipexole has also ameliorated depressive symptoms of PD.  Also, some experimental 
models have shown some neuro-protective effects in animals, although this has not been 
reproduced in humans.
80 
 Pramipexole is available in a wide variety of dosage strengths, 
and is also available as an extended release tablet, so as to create a steady state of 
dopamine receptor stimulation.  The extended release enhances compliance, but is also 
more expensive.
69 
 
Ropinirole (Requip) is a potent dopamine receptor agonist with high affinity for D2 and 
D3, and to a certain extent, D4.  Clinical studies have shown the symptomatic effects of 
ropinirole in treating PD, however dyskinesias are more likely when compared to 
placebo, but not when compared to levodopa.
79
  Much like pramipexole, some evidence 
of neuro-protection from ropinirole is exhibited in animal models, but has not been 
observed in human studies.
80
  Also like pramipexole, ropinirole is available in many 
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dosage strengths, as well as an extended release tablet form.  The extended release form, 
again, helps with adherence to medication regimens, but at a higher cost.
69 
 
Rotigotine (Neupro) is a dopamine receptor agonist with affinity for D2, D3, and some 
D1 receptors.  What makes rotigotine different is its route of administration – a patch that 
is a transdermal system, delivering the drug through the skin throughout the day.
67 
 Data 
suggest that rotigotine can reduce “off” time during therapy, and can adequately treat the 
symptoms of PD like the other dopamine receptor agonists mentioned.
82
  The patches 
also allow for dopamine receptor agonist treatment for those patients who have difficulty 
swallowing, which becomes more common as PD progresses.
79 
 Rotigotine was recalled 
by the FDA due to crystals that were forming on the patch, thus diminishing the overall 
drug being absorbed.  This problem has since been addressed, and the patches are 
required to be refrigerated so as to prevent this crystallization.  The patch is applied once 
daily to a different area of the body to prevent skin irritation at the site of the patch.
69 
 
Apomorphine hydrochloride (Apokyn), a non-addictive derivative of morphine, is a 
dopamine receptor agonist with high affinity for D2, D3, and D4 receptors.
79
  The most 
rapid and effective route of administration of apomorphine is subcutaneous injection.  It 
takes effect between ten and sixty minutes, and benefit can last up to two hours.
67
  Many 
types of route of administration for apomorphine have been explored – sublingual, 
intranasal, pulmonary, and even rectal administration.
69
  These pathways show some 
promise of behaving like apomorphine when it is injected subcutaneously.
79
  In some 
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countries, apomorphine is also administered via a pump for continuous dopaminergic 
stimulation.  The benefit of this pump system is a steadier stream of dopamine 
stimulation, thus eliminating the “on/off” phenomena, as well as eliminating the motor 
complications that accompany high levels or low levels of medication.  This form of 
treatment has not yet been approved by the FDA for use in the US.
83 
 
There are some specific side effects associated with dopamine receptor agonists that 
require special attention.  All dopamine receptor agonists are linked to some rare side 
effects: sleep attacks (falling asleep suddenly and without warning) and dopamine 
dysregulation syndrome.  This syndrome is a severe impulse control disorder, and 
commonly includes compulsive or addictive gambling.
 
 Another potential side effect is 
restrictive valvular heart disease, in which the fibrosis (thickening) occurs in the 
circulatory system, thus creating problems with blood flow and potentially leading to 
heart failure.  This condition is caused by ergot-derived dopamine receptor agonists.  All 
the dopamine receptor agonists mentioned previously to treat PD are considered non-
ergot derivatives, and therefore do not usually exhibit this potential risk.
 74 
 
Amantadine (Symmetrel) has been used to treat PD for decades.  Its therapeutic effects 
were first recognized when PD patients took it to guard against influenza and reported 
that their symptoms had lessened.
6 
 The mechanism of amantadine is unclear.  It is 
thought that amantadine could trigger the release of dopamine-containing vesicles, thus 
promoting dopamine’s effects.  It could also inhibit dopamine reuptake, this prolonging 
 29 
dopamine’s effects.  It is also possible that amantadine possesses dopamine receptor 
agonist activity.
84
  Amantadine has been found to decrease dyskinesias in clinical trials67  
and is particularly useful in early PD patients to delay the introduction of levodopa.
1
  It 
can relieve symptoms of rigidity, slowness, and minor gait abnormalities.
6
  In particular, 
amantadine has been shown to improve subject-reported freezing of gait, a major source 
of disability and increased risk of falls in the PD community.
85
  There is also evidence 
that amantadine can potentially curb the impulse control disorders that are observed in 
those PD patients taking dopamine receptor agonists.
86
  Common side effects of 
amantadine include dizziness, insomnia, anxiety, nausea, and vomiting.
67
  Amantadine 
may also cause ankle edema, as well as cause a skin condition called livedo reticularis, 
which is characterized by blotchy, red skin.
6
  At high dosages, it is said that amantadine 
can also cause visual hallucinations or confusion.
1
  Very rarely, it has been observed that 
amantadine use has caused corneal edema.
87 
 
Before levodopa entered center stage to treat PD, several surgical methods were 
attempted to alleviate PD symptoms.  In the late 1940s and early 1950s, there were 
several reports on the efficacy of two procedures that reduced parkinsonian tremors – 
pallidotomy and thalamotomy.
88 
 In a thalamotomy, a small region in the thalamus is 
destroyed; likewise, in a pallidotomy, portion of the globus pallidus is destroyed.  While 
these two procedures did reduce the tremors and rigidity seen in PD, they did not address 
the progression of the disease, nor did it address the other disabling features, such as 
slowness or clumsiness of movement or walking difficulties.
6
  With the discovery and 
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utilization of L-dopa in the 1960s and given their irreversible nature, surgical treatments 
were less utilized.  However, with motor complications associated with L-dopa treatment, 
there is a renewed interest in surgical procedures.
88 
 
Deep Brain Stimulation (DBS) began in 1987, when the discovery that electrical 
stimulation of functional targets within the brain was able to mimic the effects of a lesion 
(like those seen in pallidotomy and thalamotomy procedures).  The difference being, that 
DBS is reversible and adjustable.  While the therapeutic mechanisms of the procedure are 
still unknown and somewhat controversial, DBS is an effective therapy for a variety of 
neurological disease, including PD.
89
  An electrode is surgically placed into the brain and 
connected to a pulse generator.  The generator is the power source or battery of the 
system and is usually placed in the chest just beneath the skin.
67
  Once the power source 
is implanted, the patient can easily turn the stimulation on or off.  When the stimulation is 
on, an electrical current passes from the electrode to the target region.
6
  Hyperactivity of 
the subthalamic nucleus (STN) and the globus pallidus internus (GPi) is thought to be a 
manifestation of PD progression, and therefore, both of these areas are common targets 
for DBS.
89
  The thalamus is also a potential target for DBS in PD, however it has not has 
not shown to significantly control motor complications like the other two potential 
targets.
67
  STN and GPi DBS have both been shown in randomized controlled clinical 
trials to be superior to medicine alone.  Patients experience more “on” time, less 
dyskinesia, and improved UPDRS scores, sleep habits, and overall quality of life.
88
  
Several studies have been conducted to compared STN and GPi DBS.  In 2009, the NIH 
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COMPARE trial demonstrated equal motor outcomes of both procedures, and no 
significant differences in mood or cognition.  If a medication reduction is desired, then 
STN DBS is likely to be preferred.  Meanwhile, if dyskinesias or pre-existing cognitive 
issues are present, then GPi is the best choice.
90 
 However, with DBS also come certain 
risks or complications.  As with any brain surgery, there is a risk for complications during 
the procedure including hemorrhages, confusion, or seizures.  There is also the risk of 
device-related complications, including infections or malfunctions.  The final 
complications come from the electrical stimulation itself, and while this may be the most 
debilitating, most are also reversible.  Involuntary muscle contractions, abnormal eye 
movements, and dysarthria (motor speech disorders) are all potential side effects that can 
be reversed with slight alterations to the electrical stimulation.
91
  DBS has also been 
associated with impulse control disorders (much like dopamine receptor agonists),
92
 as 
well as social maladjustment and a potential increased risk of suicide.
93
  In addition, 
certain symptoms such as gait imbalance, gait freezing, and difficulty swallowing – major 
disabilities in PD – are not statistically improved by DBS.94 
 
A wide array of potential treatments is available for patients for PD.  Determining which 
course of action is best depends on the individual patient’s manifestation of PD 
symptoms and the best method to address his or her concerns. 
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Insurance 
Health care, including medications, is expensive, and few individuals can afford to pay 
the full costs.  Having health insurance allows for treatment without huge medical bills.  
Most Americans have private health insurance, or participate in public programs, such as 
Medicare or Medicaid.  According to the 2013 census, 86.6% of Americans (271.4 
million) had health insurance during 2013, and 13.4% of Americans (42 million) were 
uninsured.  64.2% of Americans (201.1 million) were covered by private health 
insurance, while 17.3% (54.1 million) were covered by Medicaid, and 15.6% (49 million) 
were covered by Medicare.
95
  Medicaid usually provides health care for low-income 
children and families, and people with disabilities.  Covered services usually include 
doctor visits, hospital care, prescription drugs, and preventative care for children, among 
others.  Medicare helps to pay for care in hospitals, nursing facilities, hospice care, and 
sometimes doctors’ services and prescription drugs.96  Many Americans are uninsured 
due to finances or pre-existing conditions, but Massachusetts is in a unique position 
because a health care reform bill was enacted within the state in 2006.  It mandated that 
residents have health insurance or pay a non-compliance fee, it made health insurance 
affordable, and it improved the market for non-group insurance through reforms.  The 
result of such a bill lowers out-of-pocket costs of health care and encourages the use of 
medical services more effectively and efficiently.
97
  Despite these encouraging facts, 
disparities still exist between people who have private insurance and those who have 
public insurance, like Medicaid or Medicare.  For example, patients on Medicaid had 
difficulty in accessing hand specialty care,
98
 Medicaid patients were 22 times less like to 
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receive a liver transplant than similar patients with private insurance,
99
 and children with 
public health care have limited access to surgical specialty when compared to similar 
patients with private health care.
100
  PD patients with private insurance report 
significantly better quality of life and self-reported disability.
101
  Disparities also exist 
within health care use among minorities as well.
102
  Black patients with PD are 
significantly more likely to use Medicaid, and it has been shown that this community is at 
a systematic disadvantage of accessing Deep Brain Stimulation (DBS) surgery.
103
  In 
addition, patients on public insurance plans, such as Medicare or Medicaid, and 
uninsured patients had significantly increased risks for postoperative complications 
within 30 days of neurosurgery.
104
  Why does this disparity exist?  It has been suggested 
that individuals with private insurance may possess better access to primary care, may 
pursue better health care options, and can more easily obtain preoperative and 
postoperative supports.  In contrast, programs such as Medicaid are specifically designed 
for the low income population and predetermines that participants belong to lower 
socioeconomic groups than those in private health care systems.  Another suggestion is 
the concept of health literacy, which is defined as the degree to which individuals 
understand basic health information and services.  Low health literacy is more likely 
found in lower socioeconomic groups and in the elderly – the vast majority of both of 
these groups are insured by Medicaid and Medicare.
105 
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Study Questions 
It is the aim of this project to analyze the Parkinson’s Disease and Movement Disorders 
Database in the hope of contributing to the background information and existing 
literature.  This database is unique for several reasons.  It is derived from Boston Medical 
Center, a hospital with a highly diverse patient population (refer to Figure Two for 
hospital racial demographics).
106
  In addition, the database was begun after the 
implementation of “Romneycare,” which required every resident of Massachusetts to 
have health insurance by law.  While several studies have compared patients with 
insurance to those without, this database uniquely allows for the comparison between 
private insurance and public insurance.  The database also contains large amounts of 
information regarding disease severity, medications, and complications.  For these 
reasons, the Parkinson’s Disease and Movement Disorders Database has important 
information to contribute to the understanding of PD as it pertains to race, sex, and 
insurance status. 
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SPECIFIC AIMS 
The purpose of this study is to analyze the Hoehn and Yahr (H&Y) scores of patients 
both ON and OFF medication, a method of ranking and analyzing disease severity in 
Parkinson’s patients.  The hypothesis of this study is that the H&Y scores are impacted 
by race, gender, and insurance status.  It is predicted that H&Y scores are lower in 
Caucasian than in other racial categories.  There is no consensus on whether women or 
men have higher H&Y scores, so one hypothesis is just as valid as the other.  It is also 
expected that those with private insurance will have lower H&Y values than those with 
public insurance.  The patient population was culled from the Parkinson’s Disease and 
Movement Disorders database associated with the neurology clinic at Boston University 
Medical Center.  Data was gathered via a survey and included information pertaining to 
demographics, medications, side effects, family history, and other key parameters.   
The specific aims were to: 
1) Perform a univariate analysis of study variables (gender, race,  and insurance status) and 
potential confounders (age, education, and the years between onset and enrollment into 
the database) as each pertains to the H&Y scores ON and OFF medication 
2) Perform a multivariate analysis of gender, race, insurance status, and confounding 
variables to determine the independent effects on H&Y scores ON and OFF medication 
3) Perform a secondary analysis of gender, race, and insurance status as each pertains to 
common side effects of disease progression and treatment, including: compulsive 
behavior, hallucinations, dyskinesia, motor fluctuations, dementia, orthostatic 
hypotension, depression, freezing, psychosis, and other autonomic dysfunctions 
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These questions will elucidate the clinical features of PD patients from a highly diverse 
patient population.  In addition, the analysis of the effect of public insurance versus 
private insurance has not yet been analyzed in the established literature. 
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METHODS 
Patients and Database 
Patients were recruited from a movement disorders clinic in the neurology department at 
Boston University Medical Center (BUMC) in Boston, Massachusetts between the years 
2007 and 2012.  Patients were eligible if they were diagnosed with a movement disorder 
(PD, essential tremor, and others) by a movement disorder specialist in the clinic.  New 
patients, as well as patients that were already being treated by a neurologist at the clinic, 
were eligible for the study.  Patients were treated by the movement disorder specialist, 
relevant information was gathered, the specialist filled out the survey form (to be 
discussed in the following section) while referring to medical records to verify 
information, and the subjects were then entered into the Parkinson’s Disease and 
Movement Disorders Database, along with the Hoehn & Yahr (H&Y) score, both ON and 
OFF medication.  There are 673 subjects in the Movement Disorders database.  Only 
those diagnosed with PD were included in the analysis, a total of 452 subjects.  To ensure 
confidentiality, the database used was de-identified, lacking the subjects’ names and any 
other identifying information.  The database was saved on a password-protected data 
stick, and the electronic file was itself password protected. The Institutional Review 
Board (IRB) at BUMC designated an exemption status for this project because of the 
steps taken to ensure confidentiality. 
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Survey Content 
The survey contains questions regarding demographics, family history, disease category, 
medications, and surgical history.  First, the subject’s full name (omitted from the de-
identified database), date of birth (month and day were omitted), address (omitted), 
primary language, and insurance provider were all reported.  Then, a racial category was 
chosen that best reflected their background, their education level was identified, and their 
occupational background was indicated.  The date at which the disease began to manifest 
itself (date of onset) and the date when the formal diagnosis of a movement disorder was 
made (date of diagnosis) were listed.  Any related diseases diagnosed in their parents, 
grandparents, siblings, and children, as well as their own current diagnosis (or diagnoses) 
were included.  These types of diagnoses included forms of dementia, types of dystonias 
(sustained muscle contractions), and other neurological disorders.  Then, it was indicated 
which (if any) complications of the disease or treatment were experienced.  These 
complications include compulsive behaviors, dyskinesia, dementia, depression, freezing, 
hallucinations, motor fluctuations, orthostatic hypotension, psychosis, or any other 
autonomic dysfunction.  Finally, any therapeutic surgical treatments the subject had 
undergone, as well as current and past use of medications, were recorded.  These 
medications could be specific to the treatment of the movement disorder, or they could be 
of more general use, such as antidepressants or anti-inflammatory agents. 
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Statistical Analysis 
All statistical analyses were performed using JMP version 11.0.0.  As with any database, 
there are times when information is missing and the field in the database is left blank.  If 
data was missing, then JMP excluded that data point from that particular statistical 
analysis.  Due to small numbers in certain racial categories, some were combined to 
enable statistical analysis.  African – Black (Sub-Sahara), African North (Sahara or 
Northern Regions: Algeria, Egypt, Morocco, Tunisia, Etc.), and American – Black 
(African descent, originating in: Canada, Caribbean, Brazil, US, etc.) were combined into 
the racial group Black or African.  Spanish (Cuban, Iberian Peninsula, Mexican, South or 
Central American, or Other Spanish Origin) was renamed Hispanic.  The distinction 
between white Hispanic and black Hispanic is not addressed in the survey content, and 
therefore cannot be analyzed in this statistical analysis.  The Caucasian category was 
maintained.  All other racial groups were combined into the category “Other”, due to the 
small number of patients within each category.  Likewise, there were only four patients 
that were classified as Self-Pay under insurance classification.  These four patients were 
combined with patients under public insurance, since it is likely that these patients had no 
health insurance when they arrived at the neurology clinic, and possibly, were then 
enrolled in some form of public coverage.  It is also possible that these self-pay subjects 
paid cash for treatments because they are from a different country and aren’t eligible for 
insurance in Massachusetts. 
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The association between H&Y ON and OFF medication with gender, race, and insurance 
classification were examined using univariate analyses.  To test for differences between 
the means, a Student’s t-test was used for gender and insurance status, since both 
categories only contained two factors.  For race, which contains four factors, a One-way 
ANOVA was used, and if there was statistical significance, it was followed by the Tukey-
Kramer test for individual pairs.  Education level, a potential confounder, was also 
analyzed using a One-way ANOVA, followed by the Tukey-Kramer test if statistical 
significance was reached.  Two other variables were analyzed as known confounders.  
One is age, and the other variable is the amount of time (in years) between the onset of 
PD and enrollment into the database (onset information).  Both were analyzed via a 
regression model.  Age and onset data, as known PD confounders, were also analyzed as 
each pertains to gender, race and insurance status.  Much like the primary outcomes, race 
and education level were analyzed via a One-way ANOVA, while gender and insurance 
status were analyzed using a Student’s t-test.  This analysis was performed to address 
what confounding effects there variables had (if any) on gender, race, and insurance 
status. 
 
A multivariate regression model analysis was run with the H&Y ON and OFF medication 
values as outcomes, and gender, race, age, years between onset and enrollment, and 
finally insurance status as predictors.  After it was determined that education was not a 
confounder, it was excluded from all further analyses.  Due the large number of subjects 
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excluded in this analysis (89 subjects are missing onset data), the regression models were 
run again, excluding this confounder. 
 
The secondary outcomes of disease and treatment complications are dichotomous 
outcomes, classified as either being present or absent.  Therefore, the associations with 
gender, race, and insurance status were examined via Chi-square tests.  Some 
complications did not have sufficient numbers to accommodate a valid Chi-square 
analysis – these were not pursued in further analyses.  For any complication with a 
statistically significant Chi-square value for any predictor, a logistic regression model 
was run for that complication that included gender, race, age, and insurance status.  Onset 
data, lacking a large number of subjects due to missing data, was excluded form the 
logistic regression analysis.  Education was also not included due to the determination 
that it was not a confounder.  Odds ratios, confidence intervals, and p-values were 
calculated from this analysis. 
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RESULTS 
Primary Outcomes 
The demographics of the study population listed 57.7% of the population as male, and 
58.0% of the population had public insurance or self-pay.  The ages of the subjects 
reflected a normal distribution, with 93.36% of subjects falling between the ages of 50-
89, and 62.83% of the subjects between the ages of 60-79 (Table Two).  The mean age 
was 68.4 years with a standard deviation of 10.5 years.  As described in the Methods 
section, the racial categories as they appeared on the survey (Table Three) were 
combined to form the new categories (Table Two).  83.0% of the subjects in the 
population were Caucasian, and the next biggest category was Black or African making 
up 6.2% (Table Two).  The education level of this study sample was slightly skewed, 
with 50.7% having a college degree or higher (Table Two).  Finally, the variable of 
“years between onset and enrollment” had a very wide range (0 – 40 years), but over half 
the subjects fell between zero and ten years in this category.  Only 2.43% of subjects had 
26 years or more between onset and enrollment (Table Two).  The mean amount of time 
between onset and enrollment was 9.4 years with a standard deviation of 7.0 years. 
 
Missing data was present for each study variable, but was between 1-2% in half of the 
variables.  For insurance status, 10.2% of subjects had missing data.  Under education, 
16.2% of subjects had no data listed.  Finally, under “years between onset and 
enrollment”, 19.7% of subjects had missing data (Table Two).  Missing gender data was 
sprinkled amongst the racial groups and was not specific to one category.  In addition, 
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missing race information was approximately equal between males and females (Table 
Four).  Missing gender information was split between those who also had insurance 
information missing and those with public insurance or self-pay.  There were slightly 
more men with missing insurance information than women (Table Four).  Missing race 
information was approximately equal between private insurance and public insurance and 
self-pay.  Of the 46 subjects with missing insurance information, 41 of them were 
Caucasian (Table Four). 
 
A univariate analysis of gender, race, insurance classification, education, age, and “years 
between onset and enrollment” as they pertain to both H&Y scores ON and OFF 
medication (the two primary outcomes) was performed (Table Five).  The H&Y score 
ON medication was statistically significant to onset data according to the regression 
model run (p-value 0.008), which indicated that as the time from onset increases, the 
H&Y score ON medication also increases.  However, it was not significantly related to 
any of the other variables according to the student’s t-tests or the ANOVA analyses.  The 
H&Y score OFF medication was significantly different between insurance categories (p-
value 0.0003) with a mean public and self-pay score of 2.42 compared to the mean 
private insurance score of 1.92.   Likewise, the H&Y score OFF medication was 
significantly different between genders (p-value 0.003), with the females scoring 2.45 
and the males scoring 2.07.  Both age and time from onset reached statistical significance 
in the H&Y score OFF medication (both p-values 0.0001).  As both of these variables 
increase, so does the H&Y score OFF medication.  Education did not reach statistical 
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significance in any category and thus was determined not to be a confounder.  Education 
was excluded from subsequent analyses. 
 
Age and onset information, determined to be confounding effects based on the univariate 
analyses, were analyzed as each pertains to the other variables (Table Six).  Age was 
seen to be significantly different between insurance classifications (p-value 0.0001).  
Subjects with private insurance were 11 years younger than patients with public 
insurance, on average.  Onset data was also significantly different between insurance 
classifications (p-value 0.005).  The average amount of time between onset and database 
enrollment of patients on private insurance was 7.8 years, while for the subjects with 
public insurance it was an average of 10.0 years.  There was also a significant difference 
between onset and enrollment between races (p-value 0.03), as it was 9.7 years on 
average in Caucasians and 5.7 years on average in Black or African patients.  A 
regression model analyzing onset data and age yielded a p-value of 0.0001.  As the time 
between onset and enrollment increased, the subjects were likely older at enrollment, and 
the age was increased.   
 
A multiple regression analysis was performed on H&Y scores ON and OFF medication, 
taking into account gender, age, race, insurance status, and “years between onset and 
enrollment” (Table Seven).  Despite significance seen in the univariate analysis, both 
gender and insurance classification were not seen to contribute significantly to the H&Y 
score OFF medication (p-value for gender 0.10; p-value for insurance classification 0.71).  
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Age contributed significantly (p-value 0.0003) as did the “years between onset and 
enrollment” (p-value 0.0001).  As both of these variables increase, so does the H&Y 
score OFF medication.  Despite no significance in the univariate analysis, there was 
significance under the racial categories.  Black or African patients were 0.46 points 
higher when compared to Caucasian patients controlling  for all the other variables (p-
value 0.03).  When analyzing the regression model of H&Y score ON medication, only 
“years between onset and enrollment” reached statistical significance (p-value 0.02).  As 
the time between onset and enrollment increases, so does the H&Y score ON medication.  
This variable is the only one contributing to the H&Y score ON medication outcome, 
according to the statistical analysis. 
  
A large number of subjects were excluded from the multiple regression analysis due to 
missing data under the category “years between onset and enrollment”.  A second round 
of multiple regression analyses was run for H&Y scores ON and OFF medication without 
this variable included (Table Eight).  Age was shown to still be a contributing factor to 
H&Y scores OFF medication (p-value 0.0001), increasing the score 0.04 points per year.  
Race was not statistically significant in any category (p-values 0.83, 0.81, and 0.46 for 
categories Black or African, Hispanic, and Other respectively as compared to the 
reference category, Caucasian).  There was still no significant statistical contribution 
from the insurance classifications either (p-value 0.62), despite the significance seen in 
the univariate analysis.  Gender was seen to be statistically significant (p-value 0.01), 
with an H&Y score 0.16 points higher in women as compared to men.  The multiple 
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regression analysis performed on the H&Y scores ON medication likewise took into 
account gender, age, race, and insurance status.  None of these factors reached statistical 
significance. 
 
Secondary Analysis 
The univariate relationship of several PD complications as they relate to gender, race, and 
insurance status were analyzed (Table Nine).  Significant statistical differences between 
genders were observed in the following complications: dyskinesia (p-value 0.0001), 
motor fluctuations (p-value 0.0007), and freezing (p-value 0.006).  Women had more 
dyskinesia and motor fluctuations than men, while men had more freezing than women.  
Significant statistical differences between insurance categories were observed in the 
following complications: hallucinations (p-value 0.001), dyskinesia (p-value 0.04), 
dementia (p-value 0.001), and other autonomic dysfunctions (p-value 0.02).  The 
percentage of subjects with public insurance or those who self-pay was higher for each of 
these complications than the percentage of subjects on private insurance.  There was no 
statistical significance between racial categories for any of these complications. 
 
Multiple logistic regression analyses were performed on each complication that displayed 
a statistically significant p-value in any of the three variables analyzed via Chi-square test 
(Table Ten).  Hallucinations, which only had significance between insurance categories, 
was an effect of age (p-value 0.0004, odds ratio: 1.05), rather than insurance (p-value 
0.28).  As age increases, so does the likelihood of experiencing hallucinations. 
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The regression model of dyskinesia showed statistical significance between genders (p-
value 0.0001).  The odds ratio was 2.35 in this analysis, meaning women were more 
likely to have this complication.  Insurance classifications also reached significance for 
the dyskinesia logistic regression (p-value 0.03), and the odds ratio was 1.75.  This 
indicates subjects on public insurance and self-pay are more likely to experience this 
complication than subjects on private insurance.  Finally, the odds ratio was 0.23 for the 
Black or African category as compared to the Hispanic racial category (p-value 0.03) for 
dyskinesia.  Black or African patients, therefore, are less likely to experience dyskinesia 
than Hispanic patients. 
 
Motor fluctuations, which were only statistically significant between genders in the Chi-
square analysis, were still significantly different between both genders (p-value 0.007) 
and had an odds ratio of 1.76.  Like dyskinesias, females are more likely to experience 
motor fluctuations than males.  Insurance status was statistically significant in the motor, 
meaning people with private insurance are less likely to experience motor fluctuations.  
Age also had a modest, but statistically significant contribution to motor fluctuations (p-
value 0.05), with an odds ratio of 0.98.  This means that the likelihood of experiencing 
motor fluctuations actually decreases with age. 
 
The regression model for dementia displayed significant p-values for age (p-value 
0.0002) and a modest odds ratio of 1.06.  Similarly, the category of “other autonomic 
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dysfunction” had an effect of age (p-value of 0.05) and minor odds ratio of 1.03.  As age 
increases, so does the likelihood of experiencing dementia and some “other autonomic 
dysfunction.”  There was statistical significance between genders (p-value 0.03) for 
dementia, and an odds ratio of 0.55.  Likewise, there was also a difference between 
genders in the category “other autonomic dysfunction” (p-value of 0.04) and an odds 
ratio of 0.55 comparing females to males.  Women are less likely to experience dementia 
and other autonomic dysfunctions than men. 
 
The freezing complication had several significant comparisons.  Gender (p-value 0.01) 
had an odds ratio of 0.49 comparing females to males, indicating women are less likely to 
experience freezing.  Age (p-value 0.02) had an odds ratio of 1.04.  As age increases, so 
does the likelihood of experiencing freezing.  Finally, there was some significance 
between racial comparisons: Caucasian as compared to Other (p-value 0.02) had an odds 
ratio of 0.25, and Black or African as compared to Other (p-value 0.03) had an odds ratio 
of 0.20.  Therefore, both Caucasians and Black or African subjects are less likely to 
experience freezing than the subjects included in the Other racial category. 
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DISCUSSION 
This study attempted to analyze demographic information and its relationship to PD.  The 
variables of interest were gender, race, and insurance classification.  The primary 
outcome of this study was the Hoehn and Yahr (H&Y) scoring system – a method of 
ranking the PD progression in a patient.  The H&Y scoring system is mostly whole 
numbers that rank disease progression, and are major milestones in PD.  The exceptions 
to the whole number ranking system are the values 1.5 and 2.5, which were added to the 
original scale to address some symptoms not originally included in the 1967 system and 
paper.  For this reason, a half-stage change can be considered clinically significant.  
Education level was addressed as a possible PD predictor, but was excluded after 
observing no significant contributions following the univariate analysis.  Age and “years 
between onset and database enrollment” were included in analyses as confounders.  Some 
analyses excluded onset data due to high numbers of missing data. 
 
Race 
Despite the highly diverse patient population at BUMC (Figure Two), the study 
population has an overwhelming number of Caucasians.  It has been reported that this 
racial group has a higher incidence and prevalence of PD than other racial groups.  While 
it is unsurprising to have a larger Caucasian population, the large disparity seen in this 
population is striking, and may affect the power of the analyses.  In addition, studies have 
displayed similar incidence and prevalence data in the Latino community and Caucasians.  
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Due to this information, it was expected that the Hispanic racial category was to be 
larger. 
 
It has been demonstrated that black PD patients exhibit greater disease severity and 
disability than Caucasian PD patients.  Surprisingly, the results of the univariate ANOVA 
analyses yielded no significant differences between racial categories in either of the 
primary outcomes (H&Y ON and OFF medication).  However, in the multivariate 
regression analysis, Black or African PD patients are 0.46 points higher on the H&Y OFF 
medication scale than white patients.  Advancing from one H&Y stage to the next is 
considered a disease progression of major clinical significance.  Therefore, black subjects 
are half a stage ahead of white subjects in disease progression, while all the other 
variables are held constant.  It has been thought that this disparity seen between black 
patients and Caucasian patients was due to under-reporting of symptoms and, as a result, 
delayed treatment.  However, this analysis rejects this possible explanation.  According to 
the onset data, Black or African patients are enrolled into the database sooner than any 
other racial category following disease onset.  This means that delayed treatment is no 
longer a viable explanation.  To further prove this point, when onset data is excluded 
from the regression analysis, the statistical significance seen in the racial categories 
disappears.  Therefore, a different explanation is needed to explain this disparity.  It could 
be the result of overall poorer health in the black community.  It is known that minorities 
are usually of a lower socio-economic class than white communities, and therefore may 
not be able to afford lifestyles choices that improve overall health, resulting in a higher 
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H&Y score.  Also, co-morbidities are more common in black PD patients and this may 
affect the overall H&Y score. 
 
The Hispanic and Other categories are not statistically significant in this analysis.  This 
may be the result of a lack of power in the analysis, derived from the small number of 
subjects in both of these categories.  In addition, the Other category includes various 
racial categories, and any effect of one group may be masked by the presence of the 
others.  On the other hand, there may be no real difference in these groups as compared to 
Caucasians, and there is nothing in the literature to cast suspicion that there should be. 
 
Both analyses run for H&Y scores ON medication yielded no statistical significance for 
any race category compared to Caucasians.  This indicates that the study sample is 
adequately medicated to address PD symptoms and progression, and that no one racial 
group has a statistical benefit or detriment over any other. Thirteen subjects had missing 
racial data and were excluded from any analysis including race.  Due to the small 
numbers of minority subjects, these data points could have some unknown impact on the 
data, but with the overwhelming number of Caucasians in the study sample, this is 
unlikely. 
 
Gender 
There are slightly more men than women in the study population, but this was expected 
because it is reported that men are more likely to develop PD than women.  Only seven 
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subjects were missing gender data, and given the high numbers of both men and women, 
this statistic is not considered detrimental to the study. 
 
In the univariate analysis, women have a greater disease severity that is statistically 
significant for the H&Y score OFF medication.  In the two multiple regression analyses 
run for H&Y scores OFF medication, gender takes on different statistical values.  When 
including “years between onset and enrollment”, there is no statistically significant 
difference between the sexes.  Excluding onset data and including more subjects, gender 
becomes statistically significant.  The question of which analysis to believe is a moot 
point.  In the analysis excluding onset information, women are higher than men by 0.16 
points, but this value, which is statistically significant, is not of clinical significance.  If 
two patients differed by 0.16 units in the H&Y scoring system (which would be 
impossible to measure or determine) then both patients would most likely be grouped into 
the same whole number ranking system and be deemed clinically equivalent.  For this 
reason, differences between H&Y scores OFF medication between genders may be 
deemed clinically insignificant.  With the varying claims found in the literature regarding 
disease severity between genders, there was no clear hypothesis as to the difference 
between H&Y scores OFF medication. 
 
Both analyses run on H&Y scores ON medication did not result in statistically significant 
differences between genders, thus indicating that men and women, overall, are 
appropriately medicated to treat PD symptoms. 
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It is believed that men are more likely to exhibit some symptoms of PD, and others are 
more common in women.  While there is no clinical difference overall between genders 
according to the regression analyses, this does not indicate that PD is the same between 
them, or that men and women are experiencing PD in the same way.  The H&Y scoring 
system is simply not designed to address these subtleties in disease manifestation. 
 
Insurance 
There were more subjects on some form of public healthcare or were considered self-pay 
at the time of their enrollment than those who had private insurance – from the patient 
population from which subjects were culled, this data is not surprising.  Unfortunately, 46 
subjects were missing insurance information, which makes up over ten percent of the 
overall subject population.  These 46 subjects were excluded from any analysis in which 
insurance information was analyzed, and may have impacted the results, had they been 
included. 
 
In the univariate analysis, the H&Y score OFF information was significantly higher in 
those subjects with public insurance or who were classified as self-pay.  According to the 
regression analysis, the H&Y score OFF medication was not observed to be statistically 
significant for insurance classification.  The statistical significance seen in the univariate 
analysis is therefore a confounded effect due to age and onset data.  Both of these 
confounding factors are greater in the public insurance or self-pay category as compared 
to the private insurance category.  As with the other variables, in both the univariate and 
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the multiple regression models of the H&Y score ON medication, insurance is not 
statistically significant at impacting the score. 
 
There is no reason to believe that insurance status will impact the disease progression of 
PD.  Instead, insurance status may reflect the treatment options available and the efficacy 
of therapy, which is then expressed in the H&Y score.  Subjects with private insurance 
possess better access to primary care and pursue better health care options.  These factors 
would suggest PD patients with private insurance should also have lower H&Y scores 
due to improved monitoring and treatments.  In addition, patients with public insurance 
are thought to belong to lower socioeconomic populations, which are known to possess 
lower health literacy.  Better health literacy translates to better overall health, which also 
should result in lower H&Y scores.  For these reasons, it was thought that both H&Y 
scores both ON and OFF medication would be lower in private insurance as compared to 
the public insurance classification. 
 
There have been no prior studies performed that compare PD patients with private 
insurance to those with public insurance – this study is the first to do so.  In this study 
population, there is no difference between the insurance classifications in terms of H&Y 
scores.  This may be due to the possibility that the H&Y is not sensitive enough to detect 
differences between these two groups.  Another possibility for this lack of a significant 
difference is the homogeneity of the study sample.  In addition to the lack of racial 
diversity, the education demographics inform us that the study population is surprisingly 
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educated, with half of the sample having a college degree or higher.  This begs the 
question of whether this study population accurately represents the background insurance 
populations.  On the other hand, this lack of significance may be a true effect, and there 
could be no difference between patients with public or private insurance. 
 
Age and Onset Data 
Much like the other variables, age is not statistically linked to H&Y scores ON 
medication.  Regardless of a subject’s age, their respective treatment appears effective at 
treating PD symptoms.  Age is statistically significant in both regression analyses run on 
H&Y scores OFF medication.  This is unsurprising, as age is a known predictor of PD, 
and has some confounding effects in the analyses run.  Despite the statistical significance, 
the clinical significance of age is minimal.  The effect of each individual year shows a 
rise in the H&Y score of 0.04 units, and therefore a decade would display an increase of 
0.4 units in the H&Y score OFF medication.  A PD patient will spend an average of two 
to three years per H&Y stage.  Therefore, the effects due to age are small and the clinical 
implications are minimal. 
 
Onset data significantly impacts both H&Y outcomes in the univariate analyses.  Earlier 
onset would suggest a longer disease duration, which would be reflected in the PD 
progression and subsequent H&Y score.  Therefore, onset data is a PD predictor, and was 
included in the regression analyses as a confounder.  Onset data is statistically significant 
not only for H&Y scores OFF medication, but it also is the only variable to be 
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statistically significant for H&Y scores ON medication.  However, much like the age data 
mentioned above, the clinical significance of its contribution to these scores is minimal. 
 
Despite the lack of clinical significance seen in this study with regard to age and onset 
data, a different study design would better address the clinical importance of these 
variables.  A cohort study design could determine the effect of age or onset over a period 
of time within subjects. 
 
Secondary Analysis 
Following the Chi-square analyses, only six complications reached significance after 
excluding any analyses with insufficient numbers.  In the logistic regression analyses 
performed on these six complications, onset data was not included due to high numbers 
of subjects that would be excluded.  Given the small prevalence of some of these 
complications in the study sample, it was thought that including as many as possible 
would make for a better secondary analysis. 
 
Age was statistically linked to hallucinations, motor fluctuations, dementia, freezing, and 
other autonomic dysfunction – five out of the six complications.  According to the 
logistic regression, motor fluctuations are actually seen to decrease per year, which is 
seen clinically.  The other four complications are all observed to increase over time 
during PD progression.  According to the literature, disease complications are more likely 
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as PD continues to progress, and therefore may be associated with age, but they are not 
considered to be caused by aging. 
 
Insurance status exhibited some significant odds ratios as well.  Those subjects with 
public insurance had an increased odds ratio of 1.75 for dyskinesia and 1.85 for motor 
fluctuations than subjects with private insurance.  Dyskinesia and motor fluctuations 
coexist clinically, so it is not surprising to find significance in both of these complications 
simultaneously.  They are both reflections of levodopa dosage and duration of PD.  This 
may indicate that levodopa dosage is not as closely monitored in public insurance as 
compared to private insurance.  Subjects on private insurance may also have more 
options to help adjust L-dopa dosage, and better coverage for adjunct medications to 
reduce the frequency of these complications.  Conversely, these effects may be the result 
of onset data, which was excluded from the secondary analysis. 
 
Gender is highly significant in the secondary analyses, reaching statistical significance in 
five out of the six categories.  Based on the odds ratios, women are 2.35 times more 
likely to experience dyskinesia than men, and 1.76 times more likely to experience motor 
fluctuations.  In the literature, dyskinesias are more prevalent in women, and as stated 
above, dyskinesia and motor fluctuations clinically coexist, so these findings were 
expected.  These statistics may indicate that females in this study sample have more 
difficulties with levodopa dosages than males.  They may also suggest that women may 
require closer medication monitoring or more frequent levodopa dosage adjustments. 
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The odds ratios also state that men are 1.82 times more likely to have dementia than 
women, 1.82 times more likely to have some other autonomic dysfunction, and 2.04 
times more likely to experience freezing than women (these values are the inverse of the 
odds ratios calculated from the regression models).  There are several issues that fall 
under the category “other autonomic dysfunction” – constipation, urinary frequency, and 
sexual dysfunction.  Sexual dysfunction is more commonly found in males than females, 
and it may be this condition that causes the statistically significant prevalence in males 
over females.  On the other hand, constipation is more common in women in PD.  
Without more information regarding the specific autonomic dysfunctions, no definite 
conclusions can be drawn.  There is no previous information in the literature regarding 
freezing of gait or dementia as they pertain to gender.  Both of these complications are 
considered part of PD progression.  According to the primary regression analyses, gender 
does not differ significantly regarding H&Y scores, and therefore doesn’t differ 
significantly in terms of PD progression.  For this reason, it is surprising that dementia 
and freezing differ between sexes.  This data could indicate that some other factor not 
analyzed in this study is a risk factor for these complications, and that the H&Y scoring 
system is not designed to address dementia in the progression of PD.  In addition, these 
complications could be affected by other medications being taken along with L-dopa, 
which are not addressed in this study. 
 
There are also some racial comparisons that reach statistical significance.  The Hispanic 
category has an odds ratio of 4.35 as compared to the Black or African category in 
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experiencing dyskinesia.  There are no previous studies that have addressed this or any 
other complication between the Latino community and the black community.  While this 
effect may be real, there are some points to consider.  Given the small number of subjects 
in both of these categories, there is reason to suspect the power of this analysis may be 
lacking.  Also, the Black or African category was the only racial group to reach clinical 
significance of a higher H&Y score.  For this reason, it isn’t expected for this racial 
category to show significantly less dyskinesia, a complication believed to be associated 
with PD progression.  Finally, dyskinesia and motor fluctuations coexist clinically, and to 
see a significant effect in one without the other is unexpected. 
 
For the freezing complication, the Other racial category has an odds ratio of 4.00 
compared to Caucasians and has an odds ratio of 5.00 compared to the Black or African 
category.  Again, given the small number of subjects in the racial category Other, the 
power of the analysis may not be sufficient to encourage much trust in these values.  In 
addition, the Other category which reaches significance in the freezing complication, is 
made up of a variety of racial backgrounds, and no meaningful conclusions can be drawn 
from it. 
 
Limitations and Future Directions 
There are several limitations to this study.  The first limitation is the issue of race.  The 
study population is almost 83% Caucasian and limits the generalizability of this study.  It 
also reduces the power of the racial analyses.  In addition to this, there is a problem with 
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the way the Latino community is reported.  It is likely that white Latino patients and 
black Latino patients were combined under the Spanish (renamed Hispanic) category, 
when they should have been separated based on their racial background.  This results in a 
mixing of racial categories, and does not accurately represent a portrait of the study 
population.  Given the small number of subjects in the Spanish category, it is unlikely 
that this mixing of racial backgrounds has a profound effect on the results.  More 
importantly, the racial information of this study sample lends credence to the role of 
genetic background to the prevalence of PD.  Prevalence cannot be tested in this study 
sample, but taking into account the highly diverse racial background from which it is 
drawn (Figure Two), one would expect a highly diverse study sample.  The fact that 
almost the entirety of this study sample is Caucasian implies a genetic influence in this 
study population. 
 
Another limitation is missing data.  Missing data impacts the study in two ways.  The first 
is that missing data, obviously, cannot be included in an analysis and therefore may have 
some unknown impact on the results.  However, subjects with missing data were totally 
excluded from regression analyses.  These subjects could not contribute what information 
they did possess to the regression analyses, reducing the study sample further.  Very few 
variables had large amounts of missing data – the exceptions being insurance data and 
onset data.  To combat missing onset data, the regression analyses of H&Y scores were 
run twice, including and excluding this data.  Missing data is common in any database, 
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but perhaps there would be less if subjects filled out the survey themselves, instead of the 
specialists doing so on the subjects’ behalves. 
 
Another limitation is the usage of H&Y scores instead of the UPDRS.  As mentioned 
earlier, the H&Y scoring system is a series of ranks based on PD progression.  These 
ranks are single whole numbers, with the exceptions of 1.5 and 2.5.  This type of scoring 
system, while useful for a quick analysis of PD, does not adequately address many of the 
subtleties of PD.  The UPDRS, alternatively, is a method of ranking and addressing 
several aspects of PD including daily activities, mood, and quality of life, in addition to 
the motor symptoms.  The UPDRS would have allowed for a study of greater depth and 
sensitivity, had it been available. 
 
While these limitations present a real problem for the study, the study itself is 
scientifically sound, and accurately portrays the PD community from BUMC.  The results 
attained tend to agree with the established literature, which encourages trust in the 
analyses. 
 
Looking towards the future, this study highlights the information that is lacking in the 
database, and can encourage more thorough collection in the future.  There is much 
information in the database that was not addressed in this current study – medication and 
family history, to name two examples.  There are still many questions that can be asked 
from this database, and it has many pieces of information to contribute to the PD 
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community and to other movement disorders.  The most immediate follow-up to this 
study would involve the collection of UPDRS scores.  If they can be determined and 
recorded, UPDRS scores would allow for a more sensitive study, and may perhaps find 
statistical and clinical significance where there was little or none in this current study.  
They would also permit more specific questions to be asked – addressing topics such as 
mood, everyday activities, and quality of life, which all make up portion of the UPDRS.  
It is also necessary to delve further into the insurance information that is available.  There 
was no statistical significance shown in this study, but with so little information known 
regarding PD in public versus private insurance, the Parkinson’s Disease and Movement 
Disorders database offers a prime opportunity to investigate this comparison further.  In 
particular, the medications that are available for private insurance as compared to public 
insurance could be analyzed and evaluated, along with complications or side effects that 
manifest within the groups. 
 
Conclusion 
Race, gender, and insurance status were all analyzed to illuminate what impact (if any) 
these variables had on the Hoehn and Yahr (H&Y) scoring system, both ON and OFF 
medication. 
 
Despite significance seen in the univariate analysis, gender does not appear to have a 
significant relationship to the H&Y scores, according to the multiple regression model.  
However, this does not indicate that males and females experience PD in similar 
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manners.  This point is strengthened by the secondary analysis, demonstrating dyskinesia 
and motor fluctuations as more likely in women, and freezing of gait, dementia, and other 
autonomic dysfunctions as more likely in men.  Some complication disparities have been 
observed in the literature, but more research is needed to elucidate the cause. 
 
Insurance status was also observed to have statistical significance in the univariate model, 
but not in the multiple regression analysis.  Despite this lack of significance, more 
research is needed for verification in a more sensitive outcome measure, such as the 
UPDRS.  Subjects on public insurance were more likely to experience dyskinesia and 
motor fluctuations which either indicate poorer L-dopa monitoring and dosage 
adjustment between these groups, or are the result of the confounding effects of onset 
data which was excluded from the secondary analysis.  There have been no studies 
performed contrasting public and private insurance in PD – it is a comparison that should 
be addressed in future studies. 
 
Racial categories exhibited no statistical significance in the univariate model, but in the 
multiple regression analysis, Black or African PD patients were found to be significantly 
higher in H&Y scores when compared to Caucasian subjects.  This replicates established 
literature, but also addresses the current hypothesis behind this disparity.  As 
demonstrated in this study, black subjects with PD had disease progression independent 
of disease onset and enrollment (treatment).  Therefore, the notion that black patients 
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seek treatment later than white patients is not a valid explanation for this disease 
disparity.  More research is required to discover the true cause.  
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APPENDIX 
Figure One – Parkinson’s Disease Medications 
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Figure Two – BUMC Hospital Racial Demographics 
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Table One – Parkinson’s Disease Medications 
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Table Two – Study Population Demographics 
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Table Three – Racial Groups as they appear on Survey 
 
 
Table Four – Missing Data 
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Table Five – Univariate Analysis 
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Table Six – Confounding Analysis 
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Table Seven – Multiple Regression Analysis 
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Table Eight – Multiple Regression Analysis without Onset Data 
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Table Nine – Chi-Square Analysis of Complications 
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Table Ten – Secondary Logistic Analysis
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